The invalidation of Lutathera's patents clears the path for Lantheus to launch its generic product. Traders should monitor FDA approval of Lantheus's ANDA (No. 217060) and any appeal by Novartis/ADACAP to the Federal Circuit. The on-sale bar ruling is fact-intensive and may face challenge, but the court's findings are strong. Expect positive sentiment on LNTH as the market prices in the generic launch opportunity.
Price Chart
Executive Summary
The District Court of Delaware ruled that all asserted patents covering Lutathera (a cancer treatment) are invalid under the on-sale bar, and that Lantheus's generic product does not infringe claim 12 of the '276 patent. Lantheus had conceded infringement of claims 3 and 8 of the '003 patent, but those claims are now invalid. This removes a major patent barrier to Lantheus launching its generic version of Lutathera, a drug with significant commercial sales.
Court Ruling Details
Key Facts
- All asserted claims of four patents (U.S. Patent Nos. 10,596,276; 12,151,003; 12,168,063; 12,161,732) were found invalid under 35 U.S.C. § 102(a) for being on sale more than one year before the effective filing date.
- Lantheus's product was found to infringe claims 3 and 8 of the '003 Patent (conceded by Lantheus) but does not infringe claim 12 of the '276 Patent.
- Curium's product was found not to infringe any asserted claims.
- The court rejected ADACAP's proposed claim construction for 'pharmaceutical aqueous solution' and adopted the plain meaning, which eliminated the only remaining dispute on the on-sale bar.
- ADACAP sold thousands of doses of Lutathera in European expanded access programs before the critical date (July 25, 2017), generating millions in revenue, which the court deemed commercial sales, not experimental.
Financial Impact
Lantheus can now proceed with its ANDA for a generic version of Lutathera, a drug with annual sales exceeding $500 million. The ruling removes patent risk and opens a significant revenue opportunity.
Risk Factors
- Novartis/ADACAP is likely to appeal the invalidity ruling to the Federal Circuit, which could reverse or remand.
- FDA approval of Lantheus's ANDA is not guaranteed and may face regulatory delays.
- Competition from Curium's 505(b)(2) product could also enter the market if its NDA is approved.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 court opinion.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-265gs3qq-LNTH |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 5d ago | 8-K | $100.10 $99.80 | ▼ −0.30% | ▲ +0.22% | $100.14 (+0.04%) |
Oct 2, 2026 24d ago | DEFA14A | $100.19 $99.95 | ▼ −0.24% | ▼ −0.79% | $100.14 (−0.05%) |
Oct 2, 2026 24d ago | 8-K | $100.19 $99.95 | ▼ −0.24% | ▼ −0.79% | $100.14 (−0.05%) |
Sep 16, 2026 5w ago | DEFA14A | $100.80 $100.55 | ▼ −0.25% | ▼ −0.38% | $100.14 (−0.65%) |
Aug 26, 2026 8w ago | PREM14A | $100.82 $100.47 | ▼ −0.35% | ▼ −1.00% | $100.14 (−0.67%) |
Aug 14, 2026 10w ago | Press Release | $100.95 $100.91 | ▼ −0.04% | ▲ +0.43% | $100.14 (−0.80%) |
Aug 6, 2026 11w ago | 8-K | $101.07 $100.95 | ▼ −0.12% | ▼ −0.73% | $100.14 (−0.92%) |
Aug 3, 2026 12w ago | 8-K / DEFA14A | $101.11 $101.50 | ▲ +0.39% | ▲ +0.59% | $100.14 (−0.96%) |
Aug 3, 2026 12w ago | DEFA14A / 8-K | $101.19 $101.11 | ▼ −0.08% | ▼ −1.88% | $100.14 (−1.04%) |
Aug 3, 2026 12w ago | Press Release | $101.19 $101.11 | ▼ −0.08% | ▼ −1.88% | $100.14 (−1.04%) |
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more — parsed and scored by AI.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers